Monday, 1 April 2019
Application of genomic disease risk profiling for the optimization of current Cancer Screening Programs
GCAT joined the European Colon cancer experts at the 2nd TRANSCOLONCAN COST Action meeting, at SKopja, North Macedonia, focused on intratumor heterogeneity (ITH) and single cell genomics applied to a tumor profiling. A panel of international experts on cancer discussed how to use germline predisposition variants, environmental factors, epigenetics, microbiome and metabolomics biomarkers to better select patients eligible to be screened.
COST Action TRANSCOLONCAN joins a multidisciplinary panel of experts from 29 countries with the aim of using innovative translational research to identify colorectal cancer biomarkers for personalized medicine that will improve screening, early detection and disease follow-up, and attain better tumor profiling, state-of-the-art functional characterization of genetic variants and new therapy approaches.
Related Links
TRANSCOLONCAN COST Action